--- title: Certis Oncology White Papers description: Certis Oncology's White Papers. Keep up with the latest developments in O-PDX and innovative Cancer Research for Patients, Oncologists and Drug Development. --- [![CERTIS](https://whitepapers.certisoncology.com/hubfs/certis-lockup-horz-color.svg "CERTIS")](https://www.certisoncology.com/) - [Home](https://www.certisoncology.com/) - Drug Developers - [CertisAI™️](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/) - [Custom Models](https://www.certisoncology.com/for-drug-developers/custom-model-development/) - [In Vitro/Ex Vivo](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/) - [In Vivo](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/) - [Imaging/Endpoints](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values/) - [Team](https://www.certisoncology.com/about-us/our-team/) - [Our Story](https://www.certisoncology.com/about-us/our-story/) - [Careers](https://www.certisoncology.com/about-us/careers/) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us/) - Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com/) - [Contact](https://www.certisoncology.com/contact-us/) [Database Login](https://oncointel.certisoncology.com) ![CTA_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg "CTA_KRAS-CertiScreen-824x424-1-720x424") ### VALIDATE YOUR KRAS-TARGETING STRATEGY Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies. [LEARN MORE](https://www.certisoncology.com/kras-targeted-oncology-drug-development/) - [Home](https://www.certisoncology.com/) - Drug Developers - Drug Developers - [CertisAI™️](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence/) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies/) - [Custom Models](https://www.certisoncology.com/for-drug-developers/custom-model-development/) - [In Vitro/Ex Vivo](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology/) - [In Vivo](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology/) - [Imaging/Endpoints](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis/) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - Oncologists - Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - About - About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values/) - [Team](https://www.certisoncology.com/about-us/our-team/) - [Our Story](https://www.certisoncology.com/about-us/our-story/) - [Careers](https://www.certisoncology.com/about-us/careers/) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us/) - Resource Library - Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com/) - [Contact](https://www.certisoncology.com/contact-us/) ![CTA_KRAS-CertiScreen-824x424-1-720x424](https://whitepapers.certisoncology.com/hs-fs/hubfs/CTA_KRAS-CertiScreen-824x424-1-720x424.jpg?width=720&name=CTA_KRAS-CertiScreen-824x424-1-720x424.jpg "CTA_KRAS-CertiScreen-824x424-1-720x424") ### VALIDATE YOUR KRAS-TARGETING STRATEGY Combining Predictive AI + Advanced Cancer Models to Help Direct Oncology Drug Development and Clinic Research Studies. [LEARN MORE](https://www.certisoncology.com/kras-targeted-oncology-drug-development/) ![hero-headline_certainty-saves-lives](https://whitepapers.certisoncology.com/hubfs/hero-headline_certainty-saves-lives.svg) - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts/) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results/) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research/) - [Media](https://www.certisoncology.com/resources/media/) - [White Papers](https://news.certisoncology.com) ### Hot ‘N’ Cold: Decoding Glioblastoma’s Complex Immune Landscape January 20, 2026 An Integrated Preclinical Platform for GBM Immunotherapy Development This white paper presents a strategic platform for leveraging patient-derived xenografts, humanized models, and predictive technologies to identify, optimize, and translate... [Read More](https://whitepapers.certisoncology.com/hot-n-cold-decoding-glioblastomas-complex-immune-landscape) ### Beyond the Barrier: Precision Preclinical Strategies for Targeting Glioblastoma November 07, 2025 This white paper explores how integrated preclinical platforms—including orthotopic PDX models, humanized systems, and AI-driven predictive analytics—can bridge the gap between preclinical research and clinical success in glioblastoma. Learn how... [Read More](https://whitepapers.certisoncology.com/beyond-the-barrier-precision-preclinical-strategies-for-targeting-glioblastoma) ### CertisAI Predictive Oncology Intelligence™ for Early Drug Development October 07, 2025 Explore potential applications of CertisAI across therapeutic modalities – from small molecules to antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), bispecific antibodies (BsAbs), and peptides – and demonstrate how this powerful... [Read More](https://whitepapers.certisoncology.com/certisai-predictive-oncology-intelligence-for-early-drug-development) ### The Naked Science Behind Going Nude: A Case for Superior PDX Models in Preclinical Cancer Research September 16, 2025 For cancer researchers advancing ADCs, cell therapies, and other targeted therapies, translational relevance of preclinical models matters more than ever. By downloading this white paper, you’ll get a comprehensive guide to selecting the most... [Read More](https://whitepapers.certisoncology.com/the-naked-science-behind-going-nude-a-case-for-superior-pdx-models-in-preclinical-cancer-research) ### Advancing Translational Oncology with 3D Cell Culture March 21, 2024 Photo Credit: Data on File. Certis Oncology (2024). The conventional drug development pipeline has delivered incredible pharmaceutical successes and blockbusters. But, recently, appreciation for the growing number of failed drug candidates that... [Read More](https://whitepapers.certisoncology.com/advancing-translational-oncology-with-3d-cell-culture) ### Certis Oncology Solution's Self-Proclaimed Poster Boy: Jeffrey Alan Dinkin November 10, 2023 It started with back pain. [Read More](https://whitepapers.certisoncology.com/certis-oncology-solutions-self-proclaimed-poster-boy-jeffrey-alan-dinkin) ### RAS Mutations in Cancer: Emerging Drug Development Strategies September 20, 2023 For four decades, the causal link between RAS mutations in cancer – including the KRAS, HRAS, and NRAS genes – has been well-accepted. But for almost as long, oncology drug development has struggled to develop RAS inhibitors, and many had long... [Read More](https://whitepapers.certisoncology.com/ras-mutations-in-cancer-emerging-drug-development-strategies) ### The Power of Predictive AI Models: Revolutionizing Cancer Research June 07, 2023 Powerful computational tools, such as predictive artificial intelligence (AI) models, are reshaping preclinical research, leading to more optimized and streamlined drug discovery and drug development pipelines.1 In drug discovery, AI can be applied... [Read More](https://whitepapers.certisoncology.com/how-predictive-ai-models-are-revolutionizing-cancer-research) ### Functional Precision Oncology: Filling the Gap Left By Genomics-Based Approaches June 01, 2023 Precision oncology (also known as personalized medicine in cancer treatment) is about matching an individual to the optimal therapy for their unique form of cancer. Many people associate personalized medicine with genetic testing. Genomic tumor... [Read More](https://whitepapers.certisoncology.com/functional-precision-oncology) ### How to Overcome the Translation Gap in Cancer Research March 28, 2023 Custom Solutions, Better Translation The ultimate goal of drug development in oncology is to identify drug candidates that will successfully advance through the clinical trial pipeline to FDA approval, thus offering individuals with cancer the hope... [Read More](https://whitepapers.certisoncology.com/overcoming-the-translational-gap-in-oncology-research-custom-model-development) Prev [1](https://whitepapers.certisoncology.com/page/1) [2](https://whitepapers.certisoncology.com/page/2) [3](https://whitepapers.certisoncology.com/page/3) [Next](https://whitepapers.certisoncology.com/page/2) ![Certis](https://whitepapers.certisoncology.com/hubfs/certis-logo-lockup-white.svg "Certis") 5626 Oberlin Drive, Suite 110 San Diego, CA 92121 Drug Development: 858-988-1033 Patients & Oncologists: 858-228-4110 Main: 858-952-1820 - #### Drug Developers - [CertisAI™](https://www.certisoncology.com/for-drug-developers/predictive-oncology-intelligence) - [Cancer Models](https://www.certisoncology.com/for-drug-developers/cancer-models-preclinical-studies) - [Custom Model Development](https://www.certisoncology.com/for-drug-developers/custom-model-development) - [In Vitro/Ex Vivo Pharmacology](https://www.certisoncology.com/for-drug-developers/in-vitro-ex-vivo-pharmacology) - [In Vivo Pharmacology](https://www.certisoncology.com/for-drug-developers/in-vivo-pharmacology) - [Imaging/Endpoint Analysis](https://www.certisoncology.com/for-drug-developers/imaging-endpoint-analysis) - [Immuno-Oncology](https://www.certisoncology.com/for-drug-developers/immuno-oncology/) - #### Oncologists - [Order YourPDX®](https://www.certisoncology.com/for-oncologists/order-yourpdx/) - [Clinical Research](https://www.certisoncology.com/for-oncologists/clinical-research/) - [Patient Education](https://www.certisoncology.com/for-oncologists/patient-education/) - #### Resource Library - [Cancer Facts](https://www.certisoncology.com/resources/cancer-market-facts) - [Clinical Results](https://www.certisoncology.com/resources/clinical-results) - [Supporting Research](https://www.certisoncology.com/resources/supporting-research) - [Media](https://www.certisoncology.com/resources/media) - [White Papers](https://news.certisoncology.com/) - #### About - [Mission, Vision & Values](https://www.certisoncology.com/about-us/mission-vision-values) - [Team](https://www.certisoncology.com/about-us/our-team) - [Our Story](https://www.certisoncology.com/about-us/our-story) - [Careers](https://www.certisoncology.com/about-us/careers) - [Company News](https://www.certisoncology.com/about-us/news/) - [Contact Us](https://www.certisoncology.com/contact-us) - [Login](https://oncointel.certisoncology.com) - [Privacy Policy](https://www.certisoncology.com/privacy-policy) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--facebook.svg)](https://www.facebook.com/CertisOncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--linkedin.svg)](https://www.linkedin.com/company/certis-oncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--twitter.svg)](https://twitter.com/CertisOncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--instagram.svg)](https://www.instagram.com/certis_oncology) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--youtube.svg)](https://www.youtube.com/channel/UCeX4_jh3RlNKxQxZ89_utjg) - [![](https://whitepapers.certisoncology.com/hubfs/social-media--blog.svg)](https://blog.certisoncology.com/) ![certis-footer-mouse](https://whitepapers.certisoncology.com/hubfs/certis-footer-mouse.svg "certis-footer-mouse") --- ©2024 Certis Oncology Solutions. All rights reserved. Testimonials appearing on this site reflect real-life experiences of those who have used our services. To protect their privacy, photos feature models.